Rainer Kramer

Rainer Kramer joined iOmx’ board of directors in June 2022. Rainer Kramer has almost three decades of experience in the pharmaceutical and biotechnology industry and is currently Chief Business Officer of Immatics, a leading TCR therapeutics company (NASDAQ: IMTX), where he is responsible for corporate business development and strategic alliances. During his career, Rainer has delivered numerous strategic partnerships and license deals encompassing technology and product deals as well as equity transactions with an aggregate value of more than $6 billion. Rainer has worked in research, business and corporate functions with increasing responsibilities at Amgen Inc., MorphoSys AG, Jerini AG, Shire PLC and Signature Diagnostics AG. Rainer Kramer holds a diploma in molecular biology and a Ph.D. from the Max-Planck-Institute for Neurobiology, Martinsried, Germany.